AKT1 and hepatocellular carcinoma: The induced miR-302a/d expression in CSCs attenuates the stemness through indirect downregulation of the Akt/β-catenin/cyclin D1 pathway, suggesting miR-302a/d is a potential biomarker in HCC stem cell therapy via targeting of E2F7 [131].